SCHEMBL3495456

SCHEMBL3495456

C=CCCN1C(=O)C2C3CCC(O3)C2C1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPM1B O75688 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
RAB9A P51151 2/20 0.38
LMNA P02545 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GMNN O75496 1/20 0.38
PPP1CC P36873 1/20 0.38
TFPI2 P48307 1/20 0.38
PPP5C P53041 1/20 0.38
PPP1CA P62136 1/20 0.38
PMP22 Q01453 1/20 0.38
TP53 P04637 1/20 0.38
CYP2D6 P10635 1/20 0.38
NFKB1 P19838 1/20 0.38
THPO P40225 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.36
ALDH1A1 P00352 4/20 0.34
POLB P06746 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13311385 1.00 PPM1B (0.38) PPM1BSMN1; SMN2TDP1RAB9ALMNA
SCHEMBL13311409 1.00 PPM1B (0.38) PPM1BSMN1; SMN2TDP1RAB9ALMNA
SCHEMBL17532429 0.83 PPM1B (0.48) PPM1BSMN1; SMN2TDP1RAB9ALMNA
SCHEMBL13311489 0.80 ALDH1A1 (0.46) PPM1BSMN1; SMN2TDP1RAB9ALMNA
SCHEMBL17532421 0.80 ALDH1A1 (0.46) PPM1BSMN1; SMN2TDP1RAB9ALMNA
SCHEMBL17532425 0.78 RAB9A (0.52) PPM1BSMN1; SMN2TDP1RAB9ALMNA
SCHEMBL13311393 0.77 PPM1B (0.43) PPM1BSMN1; SMN2TDP1RAB9ALMNA
SCHEMBL13311367 0.77 L3MBTL1 (0.42) PPM1BSMN1; SMN2TDP1RAB9ALMNA
SCHEMBL3497073 0.77 PPM1B (0.42) PPM1BSMN1; SMN2TDP1RAB9ALMNA
SCHEMBL3495026 0.77 L3MBTL1 (0.42) PPM1BSMN1; SMN2TDP1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US claimed
EP-2086534-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS Genetic Technologies Limited (AU) 2009-08-12 EP claimed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO claimed
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US disclosed
EP-2086534-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS Genetic Technologies Limited (AU) 2009-08-12 EP disclosed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS PPP1R10, TASP1, PPP5C PPM1B 30/4885SMN1; SMN2 3065/4885TDP1 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.